EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant C. parapsilosis spreading has gained traction in 2022

Judith Díaz-García iD, Marina Machado, Luis Alcalá, Elena Reigadas, Ana Pérez-Ayala, Elia Gómez-García de la Pedrosa, Fernando Gónzalez-Romo, María Soledad Cuétara, Coral García-Esteban, Inmaculada Quiles-Melero, Nelly Daniela Zurita, María Muñoz-Algarra und 6 weitere

Antimicrobial Agents and Chemotherapy · 15.11.2023 · 67 (11)

DOI: 10.1128/aac.00986-23 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 15.11.2023. Verfasst von Judith Díaz-García und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón , Madrid, Spain. Hauptthemen laut MEDLINE: Fluconazole, Candida. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MEC | Instituto de Salud Carlos III (ISCIII), EC | European Regional Development Fund (ERDF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously conducted a multicenter surveillance study on Candida epidemiology and antifungal resistance in Madrid (CANDIMAD study; 2019–2021), detecting an increase in fluconazole-resistant Candida parapsilosis . We here present data on isolates collected in 2022. Furthermore, we report the epidemiology and antifungal resistance trends during the entire period, including an analysis per ward of admission. Candida spp. incident isolates from blood cultures and intra-abdominal samples from patients cared for at 16 hospitals in Madrid, Spain, were tested with the EUCAST E.Def 7.3.2 method against amphotericin B, azoles, micafungin, anidulafungin, and ibrexafungerp and were molecularly characterized. In 2022, we collected 766 Candida sp. isolates (686 patients; blood cultures, 48.8%). Candida albicans was the most common species found, and Candida auris was undetected. No resistance to amphotericin B was found. Overall, resistance to echinocandins was low (0.7%), whereas fluconazole resistance was 12.0%, being higher in blood cultures (16.0%) mainly due to fluconazole-resistant C. parapsilosis clones harboring the Y132F-R398I ERG11p substitutions. Ibrexafungerp showed in vitro activity against the isolates tested. Whereas C. albicans was the dominant species in most hospital wards, we observed increasing C. parapsilosis proportions in blood. During the entire period, echinocandin resistance rates remained steadily low, while fluconazole resistance increased in blood from 6.8% (2019) to 16% (2022), mainly due to fluconazole-resistant C. parapsilosis (2.6% in 2019 to 36.6% in 2022). Up to 7 out of 16 hospitals were affected by fluconazole-resistant C. parapsilosis . In conclusion, rampant clonal spreading of C. parapsilosis fluconazole-resistant genotypes is taking place in Madrid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluconazoleCandidaHumansAntifungal AgentsAmphotericin BCandida parapsilosisTractionEchinocandinsCandida albicansDrug Resistance, FungalMicrobial Sensitivity TestsGlycosidesTriterpenes

Stichwörter der Autor:innen

C. parapsilosisCandidaMadridY132Fantifungal resistance

Substanzen

FluconazoleAntifungal AgentsAmphotericin BEchinocandinsibrexafungerpGlycosidesTriterpenes

Autor:innen und Institutionen

  • Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón , Madrid, Spain.
  • Instituto de Investigación Sanitaria Gregorio Marañón , Madrid, Spain.
  • CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058) , Madrid, Spain.
  • Hospital Universitario 12 de Octubre , Madrid, Spain.
  • Instituto de Investigación Sanitaria del Hospital 12 de Octubre , Madrid, Spain.
  • Hospital Universitario Ramón y Cajal , Madrid, Spain.

ORCID-Profile: Judith Díaz-García, Patricia Muñoz, Pilar Escribano, Jesus Guinea

Förderung

  • MEC | Instituto de Salud Carlos III (ISCIII)
  • EC | European Regional Development Fund (ERDF)

Zitieren

APA

Díaz-García, J., Machado, M., Alcalá, L., Reigadas, E., Pérez-Ayala, A., Gómez-García de la Pedrosa, E., Gónzalez-Romo, F., Cuétara, M. S., García-Esteban, C., Quiles-Melero, I., Zurita, N. D., Muñoz-Algarra, M., Durán-Valle, M. T., Sánchez-García, A., Muñoz, P., Escribano, P., Guinea, J., & CANDIMAD study group (2023). Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant C. parapsilosis spreading has gained traction in 2022. Antimicrobial Agents and Chemotherapy, 67(11). https://doi.org/10.1128/aac.00986-23

Vancouver

Díaz-García J, Machado M, Alcalá L, Reigadas E, Pérez-Ayala A, Gómez-García de la Pedrosa E, et al. Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant C. parapsilosis spreading has gained traction in 2022. Antimicrobial Agents and Chemotherapy. 2023;67(11). doi:10.1128/aac.00986-23

BibTeX
@article{DazGarca2023,
  author = {Díaz-García, Judith and Machado, Marina and Alcalá, Luis and Reigadas, Elena and Pérez-Ayala, Ana and Gómez-García de la Pedrosa, Elia and Gónzalez-Romo, Fernando and Cuétara, María Soledad and García-Esteban, Coral and Quiles-Melero, Inmaculada and Zurita, Nelly Daniela and Muñoz-Algarra, María and Durán-Valle, María Teresa and Sánchez-García, Aida and Muñoz, Patricia and Escribano, Pilar and Guinea, Jesus and CANDIMAD study group, CANDIMAD study group},
  title = {Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant C. parapsilosis spreading has gained traction in 2022},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {11},
  doi = {10.1128/aac.00986-23}
}
Kostenlos starten →